201 related articles for article (PubMed ID: 15160944)
1. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL).
Thieblemont C; Bouafia F; Hornez E; Dumontet C; Tartas S; Antal D; Lemieux B; Traullé C; Espinouse D; Salles G; Coiffier B
Leuk Lymphoma; 2004 Apr; 45(4):711-4. PubMed ID: 15160944
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis.
Bezares RF; Stemelin G; Diaz A; Argentieri D; Zubiaur EL; Garay G; Bartomioli M; Ryser R; Milone G
Leuk Lymphoma; 2011 Oct; 52(10):1936-41. PubMed ID: 21718136
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
Lundin J; Kimby E; Björkholm M; Broliden PA; Celsing F; Hjalmar V; Möllgård L; Rebello P; Hale G; Waldmann H; Mellstedt H; Osterborg A
Blood; 2002 Aug; 100(3):768-73. PubMed ID: 12130484
[TBL] [Abstract][Full Text] [Related]
4. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria.
Fiegl M; Falkner A; Hopfinger G; Brugger S; Zabernigg A; Bauer F; Haslbauer F; Demirtas D; Grossschmidt P; Tatzreiter G; Gastl G; Greil R;
Cancer; 2006 Nov; 107(10):2408-16. PubMed ID: 17054106
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
Hainsworth JD; Vazquez ER; Spigel DR; Raefsky E; Bearden JD; Saez RA; Greco FA
Cancer; 2008 Mar; 112(6):1288-95. PubMed ID: 18189296
[TBL] [Abstract][Full Text] [Related]
6. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission--experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG).
Wendtner CM; Ritgen M; Schweighofer CD; Fingerle-Rowson G; Campe H; Jäger G; Eichhorst B; Busch R; Diem H; Engert A; Stilgenbauer S; Döhner H; Kneba M; Emmerich B; Hallek M;
Leukemia; 2004 Jun; 18(6):1093-101. PubMed ID: 15071604
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
[TBL] [Abstract][Full Text] [Related]
8. Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia.
Badoux XC; Keating MJ; Wang X; O'Brien SM; Ferrajoli A; Faderl S; Burger J; Koller C; Lerner S; Kantarjian H; Wierda WG
Blood; 2011 Aug; 118(8):2085-93. PubMed ID: 21670470
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Rieger K; Von Grünhagen U; Fietz T; Thiel E; Knauf W
Leuk Lymphoma; 2004 Feb; 45(2):345-9. PubMed ID: 15101722
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine followed by alemtuzumab consolidation for previously untreated chronic lymphocytic leukemia: final report of Cancer and Leukemia Group B study 19901.
Byrd JC; Peterson BL; Rai KR; Hurd D; Hohl R; Perry MC; Gockerman J; Nattam S; Larson RA
Leuk Lymphoma; 2009 Oct; 50(10):1589-96. PubMed ID: 19863336
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia.
Kaufman MS; Caramanica A; Janson D; Driscoll N; Johnson C; Kohn N; Wasil T; Rai KR
Med Oncol; 2011 Jun; 28(2):532-8. PubMed ID: 20237867
[TBL] [Abstract][Full Text] [Related]
12. Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia.
Lin TS; Flinn IW; Lucas MS; Porcu P; Sickler J; Moran ME; Lucas DM; Heerema NA; Grever MR; Byrd JC
Leukemia; 2005 Jul; 19(7):1207-10. PubMed ID: 15858611
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
[TBL] [Abstract][Full Text] [Related]
14. Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence.
Faderl S; Ferrajoli A; Wierda W; O'Brien S; Lerner S; Keating MJ
Cancer; 2010 May; 116(10):2360-5. PubMed ID: 20225334
[TBL] [Abstract][Full Text] [Related]
15. A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).
Zent CS; Victoria Wang X; Ketterling RP; Hanson CA; Libby EN; Barrientos JC; Call TG; Chang JE; Liu JJ; Calvo AR; Lazarus HM; Rowe JM; Luger SM; Litzow MR; Tallman MS
Am J Hematol; 2016 Mar; 91(3):308-12. PubMed ID: 26662208
[TBL] [Abstract][Full Text] [Related]
16. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
[TBL] [Abstract][Full Text] [Related]
17. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial.
Pettitt AR; Jackson R; Carruthers S; Dodd J; Dodd S; Oates M; Johnson GG; Schuh A; Matutes E; Dearden CE; Catovsky D; Radford JA; Bloor A; Follows GA; Devereux S; Kruger A; Blundell J; Agrawal S; Allsup D; Proctor S; Heartin E; Oscier D; Hamblin TJ; Rawstron A; Hillmen P
J Clin Oncol; 2012 May; 30(14):1647-55. PubMed ID: 22493413
[TBL] [Abstract][Full Text] [Related]
18. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)-a single region experience on consecutive patients.
Eketorp Sylvan S; Lundin J; Ipek M; Palma M; Karlsson C; Hansson L
Ann Hematol; 2014 Oct; 93(10):1725-33. PubMed ID: 24844780
[TBL] [Abstract][Full Text] [Related]
19. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab.
Nosari A; Tedeschi A; Ricci F; Montillo M
Haematologica; 2008 Feb; 93(2):e30-1. PubMed ID: 18245646
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia.
Cortelezzi A; Pasquini MC; Sarina B; Bertani G; Grifoni F; Colombi M; Lambertenghi Deliliers G
Haematologica; 2005 Mar; 90(3):410-2. PubMed ID: 15749678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
